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Abstract
Introduction and Aim: The prognostic value of late gadolinium enhancement (LGE) for risk
stratiﬁcation of hypertrophic cardiomyopathy (HCM) patients is the subject of disagreement.
We set out to examine the association between clinical and morphological variables, risk factors
for sudden cardiac death and LGE in HCM patients.
Methods: From a population of 78 patients with HCM, we studied 53 who underwent cardiac
magnetic resonance. They were divided into two groups according to the presence or absence
of LGE. Ventricular arrhythmias and morbidity and mortality during follow-up were analyzed.
Results: Patients with LGE were younger at the time of diagnosis (p=0.046) and more often had a
family history of sudden death (p=0.008) and known coronary artery disease (p=0.086). On echo-
cardiography they had greater maximum wall thickness (p=0.007) and left atrial area (p=0.037)
and volume (p=0.035), and more often presented a restrictive pattern of diastolic dysfunction
(p=0.011) with a higher E/E′ ratio (p=0.003) and left ventricular systolic dysfunction (p=0.038).
Cardiac magnetic resonance supported the association between LGE and previous echocar-
diographic ﬁndings: greater left atrial area (p=0.029) and maximum wall thickness (p<0.001)
and lower left ventricular ejection fraction (p=0.056). Patients with LGE more often had an
implantable cardioverter-deﬁbrillator (ICD) (p=0.015). At follow-up, no differences were found
in the frequency of ventricular arrhythmias, appropriate ICD therapies or mortality.
Conclusions: The presence of LGE emerges as a risk marker, associated with the classical predic-
loaded from http://www.elsevier.pt, day 23/01/2015. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.tors of sudden cardiac death in this population. However, larger studies are required to conﬁrm
its independent association with clinical events.
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Expressão fenotípica da miocardiopatia hipertróﬁca e realce tardio na ressonância
magnética cardíaca
Resumo
Introduc¸ão e objetivos: O valor prognóstico do realce tardio na estratiﬁcac¸ão dos doentes com
miocardiopatia hipertróﬁca é controverso. Este trabalho pretende avaliar a associac¸ão entre a
presenc¸a de realce tardio na ressonância magnética cardíaca e características clínicas, imagi-
ológicas e prognósticas em doentes com miocardiopatia hipertróﬁca.
Métodos: De 78 doentes com miocardiopatia hipertróﬁca avaliámos retrospetivamente 53,
que realizaram ressonância cardíaca. Os doentes foram divididos em dois grupos, conforme
a presenc¸a ou ausência de realce tardio. Foi feito seguimento clínico referente a disritmia
ventricular e a morbi-mortalidade.
Resultados: Os doentes com realce tardio eram mais jovens à data do diagnóstico (p=0,046),
mais frequentemente tinham antecedentes familiares de morte súbita (p=0,008) e de doenc¸a
coronária (p=0,086). No ecocardiograma apresentavam maior espessura parietal máxima
(p=0,007); área (p=0,037) e volume indexado da aurícula esquerda (p=0,035); maior frequên-
cia de padrão restritivo de disfunc¸ão diastólica (p=0,011), com relac¸ão E/E’ mais elevada
(p=0,003); e disfunc¸ão sistólica do ventrículo esquerdo (p=0,038). A ressonância validou as
alterac¸ões ecocardiográﬁcas associadas à presenc¸a de realce tardio: maior área da aurícula
esquerda (p=0,029); espessura parietal máxima (p<0,001) e menor frac¸ão de ejec¸ão do ven-
trículo esquerdo (p=0,056). Os doentes com realce tardio mais frequentemente eram portadores
de CDI (p=0,015); não havendo diferenc¸as na frequência de episódios de disritmia ventricular,
terapias apropriadas de CDI ou mortalidade no seguimento clínico.
Conclusões: A presenc¸a de realce tardio surge como um marcador de risco, associando-se a
fatores já reconhecidos como preditores de morte súbita nesta populac¸ão. A sua associac¸ão
independente a eventos clínicos exige o estudo de populac¸ões de maior dimensão.
© 2013 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L. Todos os
direitos reservados.
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AVB atrioventricular block
CCBs calcium channel blockers
CMR cardiac magnetic resonance
HCM hypertrophic cardiomyopathy
HR hazard ratio
ICD implantable cardioverter-deﬁbrillator
LA left atrial
LGE late gadolinium enhancement
LV left ventricular
LVEF left ventricular ejection fraction
LVH left ventricular hypertrophy
OR odds ratio
NYHA New York Heart Association
ntroduction
ypertrophic cardiomyopathy (HCM) is a relatively common
ereditary disease with a prevalence of 1/500 population,
haracterized by complexity and a wide spectrum of pheno-
ypic expression and natural history.1,2Sudden death is the leading cause of mortality in young
CM patients, although the risk is low (about 1%/year);
n implantable cardioverter-deﬁbrillator (ICD) is the only
ffective preventive measure.3 Risk stratiﬁcation algorithms
d
w
eor predicting sudden death in this population have low pos-
tive predictive value and are unclear in their deﬁnition of
isk factors.3,4
Cardiac magnetic resonance (CMR) has become an essen-
ial exam in the morphological and functional assessment
f HCM. However, the prognostic value of late gadolinium
nhancement (LGE) in identifying potentially arrhythmo-
enic areas of endomyocardial ﬁbrosis is the subject of
isagreement.5
The aim of this study was to examine the association
etween LGE on CMR and clinical, imaging and prognostic
haracteristics in a Portuguese population of HCM patients.
ethods
tudy population
e performed a retrospective analysis of HCM patients fol-
owed regularly as outpatients in the cardiology department
f a central hospital who underwent CMR with LGE study.
Of a population of 78 patients with HCM, 61 underwent
MR. The reasons for not undergoing CMR were the usual
nes of ICD or pacemaker, claustrophobia, or patient refusal.The deﬁnition of HCM was based on the classic echocar-
iographic criteria (left ventricular hypertrophy [LVH]
ithout dilatation, maximum wall thickness ≥15 mm) and
xclusion of other systemic or local causes of hypertrophy.
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Table 1 Main characteristics of the study population.
Hypertension 38 (71.7%)
Type 2 diabetes 6 (11.3%)
Obstructive sleep apnea 6 (11.3%)
Atrial ﬁbrillation 16 (30.2%)
History of coronary artery disease 3 (5.7%)
History of syncope 8 (15.1%)
Family history of sudden death 9 (17.3%)
Beta-blockers 37 (69.8%)
Non-dihydropyridine CCBs 7 (13.2%)
Permanent pacemaker 5 (9.4%)
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a mutation of undetermined signiﬁcance in three (7.3%), and
the results are still awaited in 17 (41.5%).
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Eight patients were excluded: ﬁve in whom LGE study was
not possible, one with a diagnosis of cardiac amyloidosis and
two with Noonan syndrome. The ﬁnal study population was
thus composed of 53 patients.
Clinical data
The patients’ clinical data were collected from their medical
records by an investigator blinded to the results of CMR.
Baseline characteristics
The following baseline characteristics were recorded:
hypertension, diabetes, obstructive sleep apnea, coronary
artery disease, atrial ﬁbrillation, syncope, history of sud-
den death in a ﬁrst-degree relative aged <45 years, New
York Heart Association (NYHA) functional class, medication
with beta-blockers or non-dihydropyridine calcium chan-
nel blockers, previous myectomy or alcohol septal ablation,
pacemaker or ICD, resting electrocardiogram and NT-pro-
BNP level.
Screening for Fabry disease was performed in 34 (64.1%)
of the patients and for common HCM mutations in sarcomere
protein genes in 41 (77.4%).
Assessment of blood pressure response by exercise
testing
Thirty (56.6%) patients underwent exercise testing using
the modiﬁed Bruce protocol. A hypotensive response was
deﬁned as a rise of ≤20 mmHg or a fall of ≥20 mmHg in
blood pressure during exertion.
Echocardiographic parameters
Transthoracic echocardiography was performed by two
experienced observers who were blinded to some of the
patients’ clinical data. The following parameters were
assessed: left ventricular (LV) diastolic diameter; thickness
of the ventricular septum, LV posterior wall and apex; left
atrial (LA) volume; presence of a ≥30 mmHg gradient at rest
and following provocation; quantiﬁcation of mitral regur-
gitation; classiﬁcation of LV systolic function and diastolic
dysfunction.
Of the patients with no gradient at rest, 13 (33.4%) under-
went exercise echocardiography to determine the presence
of a gradient with exercise.
Cardiac magnetic resonance
All CMR studies were performed on a Philips® 1.5 T scanner
by three experienced observers who were blinded to some of
the patients’ clinical data. The following parameters were
assessed: LA area; left ventricular ejection fraction (LVEF);
maximum LV wall thickness; and LGE following intravenous
gadolinium administration.
Follow-up
The study population were followed for a mean of 53.6±53.4
months (4-271).
All patients underwent 24-hour Holter ECG monitoring to
determine the number of ventricular extrasystoles and of
episodes of non-sustained ventricular tachycardia, deﬁned
as ≥3 consecutive ventricular complexes lasting <30 s and
without hemodynamic compromise.
3
tCCBs: calcium channel blockers.
In patients with an ICD, all records of device interroga-
ion were analyzed for appropriate therapies and overdrive
acing triggered by ventricular ﬁbrillation and/or tachycar-
ia.
Two endpoints were deﬁned: all-cause death and appro-
riate ICD therapies.
tatistical analysis
he statistical analysis was performed with SPSS for Win-
ows, version 17.0.
Nominal variables were expressed as counts and percent-
ges and were compared (combination of frequencies) using
he chi-square test. Continuous variables were expressed
s means ± standard deviation; the Student’s t test was
sed to compare variables with normal distribution and the
ann--Whitney U test to compare those with non-normal
istribution.
A value of p<0.05 was considered statistically signiﬁcant.
esults
haracteristics of the study population
he study population consisted of 53 patients, 27 (50.9%)
ale, with a mean age of 56.4±17.0 years at the time of
iagnosis.
Table 1 shows the main characteristics of the population.
n terms of functional capacity, 29 (54.7%) patients were in
YHA class I, 22 (41.5%) in class II, and two (3.8%) in class III.
o patient had undergone myectomy and two had undergone
lcohol septal ablation.
Table 2 shows the main electrocardiographic alterations.
Of the 34 (64.1%) patients screened for Fabry disease,
one had any of the classical mutations.
Investigation of HCM mutations in sarcomere protein
enes, performed in 41 patients (77.4%), was negative in 12
29.3%); a classical mutation was identiﬁed in nine (21.9%),Mean NT-pro-BNP, assessed in 29 patients (54.7%), was
130±5762 pg/ml.
Only four (13.3%) of the patients who underwent exercise
esting had a hypotensive response.
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Table 2 Main electrocardiographic alterations.
Complete RBBB 5 (9.4%)
Left anterior hemiblock 16 (30.2%)
Complete LBBB 1 (1.9%)
Bifascicular block 8 (15.1%)
First-degree AVB 13 (24.5%)
Second-degree AVB 4 (7.5%)
Third-degree AVB 3 (5.7%)
Voltage criteria for LVH 37 (69.8%)
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Table 4 Main continuous cardiac magnetic resonance
variables.
LA area, cm2 31.07± 4.78
LV mass, g 173.7± 56.4
Maximum LV wall thickness, mm 19.4± 3.8
LVEF, % 65.9± 8.8
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chocardiographic ﬁndings
he phenotypic distribution of HCM was as follows: asym-
etric in 36 (67.9%) patients, apical in 13 (24.5%) and
oncentric in four (7.5%). Systolic anterior motion of the
itral valve causing obstruction at rest was observed
n 20 (37.7%) patients, with an end-systolic gradient of
9.4±27.3 mmHg. Mitral regurgitation was absent in six
11.3%) patients, minimal (grade 1) in 30 (56.6%), mild
grade 2) in 11 (20.8%), moderate (grade 3) in ﬁve (9.4%)
nd severe (grade 4) in one (1.9%).
Only seven (13.2%) patients did not present diastolic dys-
unction. A pseudonormal pattern was the most common,
ound in 22 (41.5%) patients, followed by abnormal relax-
tion in 21 (39.6%); three (5.7%) presented a restrictive
attern.
At least mild global systolic dysfunction was identiﬁed in
even (13.2%) patients.
Table 3 shows the main continuous echocardiographic
ariables.
Of the 13 patients who underwent exercise echocardi-
graphy, seven (53.8%) developed a signiﬁcant gradient on
xertion (69.3±31.9 mmHg).
ardiac magnetic resonance ﬁndings
he phenotypic characterization of HCM by CMR was simi-
ar to that obtained by transthoracic echocardiography, and
rovided more accurate localization of LVH.Table 4 shows the main continuous variables assessed by
MR.
LGE was observed in 24 (45.3%) patients.
Table 3 Main continuous echocardiographic variables.
LV diastolic diameter, mm 48.9± 7.4
Ventricular septal thickness, mm 17.2± 4.3
LV posterior wall thickness, mm 11.2± 3.3
Apical thickness (n=13), mm 18.4± 6.4
LA area (A4C), mm2 25.1± 5.6
LA volume, mm3 52.5± 20.1
E-wave velocity, m/s 0.82± 0.31
Lateral E′, cm/s 6.7± 2.4
E/E′ ratio 13.9± 6.9
A4C: apical 4-chamber view; LA: left atrial; LV: left ventricular.
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bLA: left atrial; LV: left ventricular; LVEF: left ventricular ejection
fraction.
actors predicting late gadolinium enhancement
n cardiac magnetic resonance
atients with LGE were younger at diagnosis (52.3±16.9 vs.
9.8±16.5 years; p=0.046), and more often had a family his-
ory of sudden death (33.3% vs. 3.4%; p=0.008; odds ratio
OR] 13.5).
Patients with LGE were more likely to have a history
f coronary artery disease (12.5% vs. 0%; p=0.086) and
igher NT-pro-BNP levels (5151±7882 vs. 1489±2422 pg/ml;
=0.089).
There were no differences between the groups in gen-
er (p=0.669); history of hypertension (p=0.899), diabetes
p=0.532), syncope (p=0.288) or obstructive sleep apnea
p=0.135); presence of an identiﬁed mutation (p=0.676);
YHA functional class; previous therapy with beta-blockers
p=0.454) or non-dihydropyridine CCBs (p=0.112); voltage
riteria for LVH (p=0.696); or history of atrial ﬁbrillation
p=0.098).
There was also no difference between the groups in blood
ressure response to exercise testing (p=0.348).
Patients with LGE more often presented systolic dysfunc-
ion on echocardiography, characterized by LVEF <50% (25.0%
s. 3.4%; p=0.038; OR 9.33) and diastolic dysfunction with
seudonormal (68.2% vs. 29.2%) or restrictive pattern (9.1%
s. 4.2%; p=0.011).
Table 5 shows the continuous echocardiographic variables
hat predicted LGE.
No association was seen between the presence of LGE
nd type of HCM: asymmetrical (p=0.441), apical (p=0.475)
nd concentric (p=0.844). Similarly, neither the presence of
bstruction (p=0.242) nor the severity of mitral regurgita-
ion (p=0.637) was associated with LGE.
Table 6 shows the CMR variables that predicted LGE.
ollow-up
atients were followed for a mean of 53.6±53.4 months (4-
71).
There were no differences between the groups in detec-
ion of non-sustained ventricular tachycardia (20.8% vs.
0.7%; p=0.990), or in the number of ventricular extrasys-
oles (p=0.503) documented on 24-hour Holter monitoring.
During follow-up 11 patients (20.7%) received an ICD for
rimary prevention due to the presence of one or more
lassical risk factors. More patients with LGE received ICDs
37.5% vs. 6.9%; p=0.015). An appropriate therapy with over-
rive pacing was recorded in only one patient.
Two patients died during follow-up, one in each group,
oth from heart failure.
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Table 5 Continuous echocardiographic variables that predicted late gadolinium enhancement.
Patients with LGE (n=24) Patients without LGE (n=29) p
Greater LV wall thickness, mm 18.96± 5.08 15.61± 2.82 0.007
LA area (A4C), cm2 26.85± 5.97 23.57± 4.94 0.037
Indexed LA volume, cm3 58.97± 20.77 47.05± 18.13 0.035
E/E′ ratio 16.73± 7.72 11.32± 4.96 0.003
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Discussion
CMR is the preferred imaging modality for determining ven-
tricular mass, chamber volume, global systolic function and
the pattern and distribution of LVH in HCM patients.6--8
LGE imaging is a particularly valuable method for identi-
fying areas of ﬁbrosis and to determine their extent and
distribution.9,10
Characteristics of the study population
The mean age of our population (56.4±17.0 years) was older
than in most studies in the literature5,11,12 and included few
patients in the age-group most associated with sudden death
(<35 years).
Most were asymptomatic or mildly symptomatic, as in
other published series.9,13--15 This highlights the need for
new ways to stratify risk of sudden death, since this may
be the ﬁrst clinical manifestation of HCM, years after initial
diagnosis.16,17
Although asymmetric HCM was the most common pattern
in our population (67.9%), there was a high prevalence of
apical HCM (24.5%).
The mean maximum LV wall thickness on CMR of 19.4±3.8
mm demonstrates that signiﬁcant LVH can be present even
in only mildly symptomatic patients, as reported in the
literature.13--15
The prevalence of LV outﬂow tract obstruction in our pop-
ulation (50.9%) was lower than in the literature,18 but some
patients without a gradient at rest did not undergo exercise
echocardiography.
The percentage of patients with a hypotensive response
on exercise testing (13.3%) was also lower than previously
reported (25%).19,20
Clinical and prognostic signiﬁcance of late
gadolinium enhancement
Our study conﬁrms that the presence of LGE is a common
phenotypic characteristic in this population, although its
r
p
w
t
Table 6 Cardiac magnetic resonance variables that predicted lat
Patients with LGE (n=24)
Greater LV wall thickness, mm 21.50± 4.05
LA area, cm2 32.88± 3.58
LVEF, % 63.4± 8.4
LA: left atrial; LGE: late gadolinium enhancement; LVEF: left ventriculncement.
revalence (45.3%) was lower than that described in the
iterature.21--23
The pattern of distribution of LGE does not correspond
o the perfusion territories of the epicardial coronary arter-
es, but is related to areas of LVH and is mid-myocardial in
ocation.9
Predictors of LGE were younger age, a family history of
udden death, LVEF <50%, more severe diastolic dysfunction
nd LA dilatation, and greater maximum LV wall thickness.
It is known that the presence and extent of LGE is
nversely related to LVEF,24 since LGE is associated with ven-
ricular remodeling that eventually leads to heart failure.13
n association between LGE and maximum LV wall thick-
ess has also been reported.25 LA dilatation, a surrogate
arker of diastolic dysfunction, is also associated with
GE.26
Mortality in our population, although low, was in all cases
f cardiovascular cause (heart failure).
As in previous studies,11,15 it remains to be proved
hether LGE is an independent prognostic marker. Maron
t al.12 reported a high prevalence, although not reach-
ng statistical signiﬁcance, of cardiovascular events during
ollow-up of 202 patients with HCM and LGE. By contrast,
n a study of 220 asymptomatic or only mildly symptomatic
CM patients with a mean follow-up of three years, Bruder
t al.15 showed that LGE was an independent predictor of
ardiac death (hazard ratio [HR] 8.6; p=0.038), whereas the
resence of one or two clinical risk factors did not reach
tatistical signiﬁcance (HR 1.4; p=0.68).
In a recent meta-analysis of four studies with a total
f 1063 HCM patients, Green et al.5 conﬁrmed the high
revalence of LGE (60%) and its correlation with adverse
ardiovascular events (cardiac death, heart failure death,
nd all-cause mortality), although it was not associated with
udden death or aborted sudden death and did not add value
o traditional clinical risk factors.
In a population in which 60% present LGE and the event
ate is 1--5%/year, such an association would be difﬁcult to
rove. More sophisticated techniques for quantifying LGE
ould thus improve its prognostic value.27 Quantiﬁcation of
he extent of LGE by means of T1-weighted sequences has
e gadolinium enhancement.
Patients without LGE (n=29) p
17.69± 2.57 <0.001
29.00± 5.26 0.029
68.1± 8.8 0.056
ar ejection fraction.
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een validated in other diseases of the myocardium, includ-
ng ischemic heart disease and dilated cardiomyopathy, and
ould be of value in HCM.28,29
The European Cardiovascular Magnetic Resonance reg-
stry, with a clinical follow-up of at least 12 months,
bserved only a trend towards better outcome in HCM
atients without LGE.30
tudy limitations
ur study has several limitations, including the small number
f patients and events.
Patients with ICDs who did not undergo CMR before
evice implantation were not included in the study, and it
s impossible to know whether their inclusion would have
igniﬁcantly changed its results.
Another limitation is the fact that LGE was not quantiﬁed,
or was its distribution analyzed.
As with all retrospective studies, we were limited to the
nformation available in patients’ medical records.
onclusions
he presence of LGE emerges as a risk marker, associated
ith the classical predictors of sudden cardiac death in HCM,
articularly a family history of sudden death and greater
aximum LV wall thickness. However, larger studies are
equired to conﬁrm its independent association with clinical
vents.
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